Case studies assessing a new skin barrier repair cream for the treatment of atopic dermatitis

Journal of Drugs in Dermatology

Volumn 8, Issue 11, 2009, Pages 1037-1041

  Bikowski, Joseph ^a  

^a Bikowski Skin Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; EPICERAM; FEXOFENADINE; LORATADINE; UNCLASSIFIED DRUG; CERAMIDE; CHOLESTEROL; FATTY ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; DISEASE EXACERBATION; DRY SKIN; ECZEMA; FEMALE; FOLLOW UP; HUMAN; LICHEN; MALE; PHYSICAL EXAMINATION; PRURITUS; RASH; SKIN EXAMINATION; SKIN INFECTION; SUN EXPOSURE; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; XERODERMA; DRUG COMBINATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED, 80 AND OVER; CERAMIDES; CHOLESTEROL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FATTY ACIDS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 77953083720     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-657. (Pubitemid 38544154)
2. Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol. 2006;144(1):1-9.
3. National Institute of Arthritis and Musculoskeletal Skin Diseases. Atopic Dermatitis. Handout on Health. Available at: http://www.niams.nih.gov. Accessed March 12, 2009.
4. Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004. A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55(3):490-500.
5. Leung DY. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 1999;104:S99-S108. (Pubitemid 29455072)
6. Elias PM, Choi EH. Interactions among stratum corneum defensive functions. Exp Dermatol. 2005;14(10):719-726. (Pubitemid 41419458)
7. Chamlin SL, Frieden IJ, Fowler A, et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol. 2001;137(8):1110-1112. (Pubitemid 32756480)
8. Aberg KM, Man MQ, Gallo RL, et al. Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol. 2008;128(4):917-925. (Pubitemid 351374295)
9. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337-1343.
10. Imokawa G, Abe A, Jin K, et al. Decreased level of ceramides in stratum corneum of atopic dermatitis: An etiologic factor in atopic skin? J Invest Dermatol. 1991;96(4)523-526.
11. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47(2):198-208.
12. EpiCeram® [package insert]. Bridgewater, NJ: Promius Pharma, LLC; 2008.
13. Del Rosso JQ. 27th Anniversary Fall Clinical Dermatology Conference. What's new in the medicine chest? Skin Aging. February 2009;Suppl:1-7.
14. Data on File. A prospective, randomized, investigator-blind, controlled, pilot study comparing the effect of EpiCeram device versus conservative standard of care therapy utilizing mid-strength topical steroid (fluticasone propionate 0.05%) in the treatment of atopic dermatitis in pediatric patients. Promius Pharma LLC; 2008.